Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 12

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
 was triggered by a decision to discontinue a productivity engineering project.Compensation and Related BenefitsAccrued compensation and related benefits were comprised of the following (in thousands):June 30,2025December 31,2024Accrued payroll and related costs$4,646 $2,970 Accrued bonus14,373 21,859 Accrued commissions4,187 5,938 Other2,896 2,848 Accrued compensation and related benefits$26,102 $33,615 Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities were comprised of the following (in thousands):June 30,2025December 31,2024Legal and related costs$4,661 $6,100 Royalties for licensed technologies4,306 7,042 Professional services3,849 5,315 Product warranties8,456 8,615 Taxes payable4,972 4,936 Other12,819 9,157 Accrued expenses and other current liabilities$39,063 $41,165 Product WarrantiesChanges in the reserve for product warranties were as follows (in thousands):

11

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

Six Months EndedJune 30,20252024Beginning of period$8,615 $8,116 Amounts charged to cost of revenue6,020 5,031 Repairs and replacements(6,179)(3,693)End of period$8,456 $9,454 Revenue and Deferred RevenueAs of June 30, 2025, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements or allocated amounts for extended warranty service agreements bundled with sales of instruments was $32.7 million, of which approximately $21.4 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $32.7 million and $33.2 million as of June 30, 2025 and December 31, 2024, respectively, consisted of deferred revenue related to extended warranty service agreements.The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,